Assuntos
Endotelinas/metabolismo , Endotélio Vascular/enzimologia , Hipóxia/fisiopatologia , Pulmão/metabolismo , Óxido Nítrico Sintase/metabolismo , Precursores de Proteínas/metabolismo , Animais , Doença Crônica , Endotelina-1 , Hemodinâmica , Hipertensão Pulmonar , Hipóxia/metabolismo , Pulmão/enzimologia , Masculino , Óxido Nítrico Sintase Tipo III , RatosRESUMO
While it is known that nitric oxide (NO) is an important modulator of tone in the hypertensive pulmonary circulation, the roles of cyclic 3'-5'-guanosine monophosphate (cGMP) and cGMP-phosphodiesterase (PDE) are uncertain. We found that isolated lung perfusate levels of cGMP were over ninefold elevated in hypertensive vs. normotensive control rats. 98-100% of lung cGMP hydrolytic activity was cGMP-specific PDE5, with no significant decrease in PDE activity in hypertensive lungs, suggesting that the elevation in cGMP was due to accelerated production rather than reduced degradation. In pulmonary hypertensive rat lungs, in vitro, cGMP-PDE inhibition by E4021[1-(6-chloro-4-(3,4-methylbenzyl) amino-quinazolin-2-yl)piperdine-4-carboxylate], increased perfusate cGMP threefold, reduced hypoxic vasoconstriction by 58 +/- 2%, and reduced baseline pulmonary artery pressure by 37 +/- 5%. In conscious, pulmonary hypertensive rats, intravenous administration of E4021 reduced hypoxic vasoconstriction by 68 +/- 8%, pulmonary artery pressure by 12.6 +/- 3.7% and total pulmonary resistance by 13.1 +/- 6.4%, with no significant effect on cardiac output, systemic pressure, and resistance. Comparison of E4021 to inhaled nitric oxide demonstrated that cGMP-PDE inhibition was as selective and as effective as inhaled NO.
Assuntos
3',5'-GMP Cíclico Fosfodiesterases/antagonistas & inibidores , Hipertensão Pulmonar/fisiopatologia , Hipóxia/fisiopatologia , Pulmão/enzimologia , Circulação Pulmonar/fisiologia , Vasodilatação/fisiologia , 3',5'-GMP Cíclico Fosfodiesterases/metabolismo , Animais , Bloqueadores dos Canais de Cálcio/farmacologia , GMP Cíclico/metabolismo , Diltiazem/farmacologia , Hemodinâmica , Técnicas In Vitro , Pulmão/irrigação sanguínea , Masculino , Óxido Nítrico/farmacologia , Perfusão , Inibidores de Fosfodiesterase/farmacologia , Piperidinas/farmacologia , Purinonas/farmacologia , Quinazolinas/farmacologia , Ratos , Ratos Sprague-DawleyRESUMO
Exposure to chronic hypoxia results in a lower resting heart rate and a blunted cardiovascular responsiveness to beta-adrenergic receptor stimulation. Possible effects of acclimatization to high altitude on the binding of [125I]iodohydroxybenzylpindolol to beta-adrenergic receptors on membranes of right and left ventricles of rat heart were determined. Chronic high-altitude exposure led to a decrease in the density of beta-adrenergic receptors in nonhypertrophied left ventricles as well as in hypertrophied right ventricles. The affinity of the receptor for the radioligand was not changed by the exposure to high altitude, suggesting that the properties of the receptor were not affected. Basal and isoproterenol-stimulated adenylate cyclase activities were decreased in membranes prepared from hearts and pulmonary arteries of rats acclimatized to high altitude. The loss of cardiac beta-adrenergic receptors in rats adapted to high altitude was prevented by the chronic coadministration of a low dose of DL-propranolol. The results suggest that changes in beta-adrenergic receptor density may partially explain the hemodynamic adaptation that occurs with chronic hypoxia. These decreases may be due to a loss of functional beta-adrenergic receptors caused by chronically elevated concentrations of circulating neurally released catecholamines.